My Therakos

Your account provides access to Webinars and if you are a customer you can also access system documents, events and e-learning

Register today without any obligation or fees.

For over 30 years, we have played a pioneering role in advancing the science of immunotherapy delivered through ECP. We continue to invest in the highest standards of medical education, while seeking to refine our technologies, and remaining dedicated to furthering advances in ECP Immunomodulation.

By registering with MyTHERAKOS, you can take advantage of our event calendar, keep up to date with upcoming webinars and watch those you missed on demand.

If you have a CELLEX^TM System, you will also have exclusive access to the E-Learning platform and a dashboard where you can see the status of your orders, operator manuals, technical bulletins and much more.

Registration to MyTHERAKOS is for healthcare professionals only and is not intended for use in the US and Canada.

Your MyTherakos account gives you access to:

Live Webinars

Live and on-demand webinars, from experienced key opinion leaders. Register for upcoming webinars and quickly review webinars you've already attended.

Member Events

We're more than webinars. The Therakos Institute host symposia, centres of excellence, meet and ask the expert sessions. By creating your MyTHERAKOS account, you can access everything easily.

Exclusive Content

We're continually updating content available within MyTHERAKOS and content from the Therakos Institute. Available to any HCP looking to learn more about ECP.

If you have a CELLEX^TM Photopheresis System in your healthcare facility, you'll also see:

Management Dashboard

Handle everything around your system orders in one simple place including service requests and invoices.

E-learning - Operator Resources

Guidance and materials you need to operate your CELLEX^TM System.

Resource Library

Our operators resources include reference guides, technical bulletins, training materials and user manuals.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease.
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.
Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOS^TM CELLEX^TMPhotopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.